Top 29 medical and healthcare startups in Switzerland
Feb 16, 2026
|
Like
17
1
Funding: $2.5B
Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. It is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas.
Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. It is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas.
2
Funding: $1B
ADC Therapeutics is focused on the creation of proprietary Antibody Drug Conjugates (ADCs) for the therapy of both solid and hematological cancers. It uses monoclonal antibodies specific to specific tumor antigens conjugated to a innovative class of highly potent pyrrolobenzodiazepine (PBD)-based warheads to specifically kill cancer cells. The company is expanding ZYNLONTA into earlier stages of DLBCL and indolent lymphomas. In addition, IND-enabling efforts are in progress for the Company’s exatecan-based, prostate-specific membrane antigen.
ADC Therapeutics is focused on the creation of proprietary Antibody Drug Conjugates (ADCs) for the therapy of both solid and hematological cancers. It uses monoclonal antibodies specific to specific tumor antigens conjugated to a innovative class of highly potent pyrrolobenzodiazepine (PBD)-based warheads to specifically kill cancer cells. The company is expanding ZYNLONTA into earlier stages of DLBCL and indolent lymphomas. In addition, IND-enabling efforts are in progress for the Company’s exatecan-based, prostate-specific membrane antigen.
3
Funding: $365.4M
ALENTIS Therapeutics develops novel therapeutics for the treatment of advanced liver fibrosis and liver cancer. The company is developing a portfolio of antibody-drug conjugates (ADCs) and monoclonal antibodies against its therapeutic target, claudin-1. Its unique antibodies specifically target exposed claudin-1 to open the rigid extracellular matrix, block disease signals and, in cancer, selectively kill tumor cells. ALENTIS's clinical candidates include the ADC ALE.P02 for the treatment of squamous cell carcinomas and the monoclonal antibody lixudebart for the treatment of organ fibrosis. In addition to clinical development, its preclinical programs include other anti-claudin-1 therapies, including other ADCs.
ALENTIS Therapeutics develops novel therapeutics for the treatment of advanced liver fibrosis and liver cancer. The company is developing a portfolio of antibody-drug conjugates (ADCs) and monoclonal antibodies against its therapeutic target, claudin-1. Its unique antibodies specifically target exposed claudin-1 to open the rigid extracellular matrix, block disease signals and, in cancer, selectively kill tumor cells. ALENTIS's clinical candidates include the ADC ALE.P02 for the treatment of squamous cell carcinomas and the monoclonal antibody lixudebart for the treatment of organ fibrosis. In addition to clinical development, its preclinical programs include other anti-claudin-1 therapies, including other ADCs.
4
Funding: $340.7M
MindMotionPro is a CE-Marked hospital based solution for early motor rehabilitation post-stroke. An engaging and motivational virtual reality rehabilitation program that supports individual recovery goal.
MindMotionPro is a CE-Marked hospital based solution for early motor rehabilitation post-stroke. An engaging and motivational virtual reality rehabilitation program that supports individual recovery goal.
5
Funding: $268M
Basilea Pharmaceutica is a commercial stage biopharmaceutical company that develops and commercializes innovative medicines in the therapeutic area of anti-infectives
Basilea Pharmaceutica is a commercial stage biopharmaceutical company that develops and commercializes innovative medicines in the therapeutic area of anti-infectives
6
Funding: $265.2M
Sophia Genetics aims to bring data analytics solutions to the market, to support healthcare professionals by maximizing the power of data-driven medicine. It achieves this mission through the adoption of SOPHiA AI, which is built using techniques such as statistical inference, pattern recognition, and machine learning.
Sophia Genetics aims to bring data analytics solutions to the market, to support healthcare professionals by maximizing the power of data-driven medicine. It achieves this mission through the adoption of SOPHiA AI, which is built using techniques such as statistical inference, pattern recognition, and machine learning.
7
Funding: $214.7M
SkyCell focuses on developing temperature controlled logistics containers for the pharmaceutical industry.
SkyCell focuses on developing temperature controlled logistics containers for the pharmaceutical industry.
8
Funding: $108.8M
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis.
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis.
9
Funding: $101.8M
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
11
Funding: $87.1M
Genkyotex is the leading developer of NOX inhibitors. We are developing first-in-class, small molecule therapeutics that selectively inhibit NOX enzymes. NOX enzymes are key drivers in multiple diseases including fibrotic, inflammatory, cardiovascular and CNS diseases and oncology.
Genkyotex is the leading developer of NOX inhibitors. We are developing first-in-class, small molecule therapeutics that selectively inhibit NOX enzymes. NOX enzymes are key drivers in multiple diseases including fibrotic, inflammatory, cardiovascular and CNS diseases and oncology.
12
Funding: $76M
CDR-Life AG is a biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology.
CDR-Life AG is a biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology.
13
Funding: $65.7M
NBE-Therapeutics develops ADCs for the treatment of solid tumors (in particular breast and pancreatic cancers). Its platform enables to develop targeted therapies that have a long-lasting immunological effect and can shrink or even completely eradicate tumors. The company has a portfolio of ADC candidates based on proprietary linker loading and conjugation technologies, which are at various stages of pipeline. The company's technologies enable to find the optimal combination of properties for each target antigen: enzymatic conjugation with the enzyme sortase A, SMAC technology (sortase-mediated antibody conjugation), a highly potent anthracycline-based intercalating toxin that damages DNA (as a payload), novel binding agents for finding any new targets and a mammalian antibody library display system. The company is financially backed by the Boehringer Ingelheim Venture Fund.
NBE-Therapeutics develops ADCs for the treatment of solid tumors (in particular breast and pancreatic cancers). Its platform enables to develop targeted therapies that have a long-lasting immunological effect and can shrink or even completely eradicate tumors. The company has a portfolio of ADC candidates based on proprietary linker loading and conjugation technologies, which are at various stages of pipeline. The company's technologies enable to find the optimal combination of properties for each target antigen: enzymatic conjugation with the enzyme sortase A, SMAC technology (sortase-mediated antibody conjugation), a highly potent anthracycline-based intercalating toxin that damages DNA (as a payload), novel binding agents for finding any new targets and a mammalian antibody library display system. The company is financially backed by the Boehringer Ingelheim Venture Fund.
14
Funding: $61M
Pioneering the next generation of non-viral gene therapy. Viral vectors have enabled early successes in the gene therapy space, but their immunogenicity, limited payload capacity and complex manufacturing are headwinds for the field. Anjarium is squarely focused on those challenges.
Pioneering the next generation of non-viral gene therapy. Viral vectors have enabled early successes in the gene therapy space, but their immunogenicity, limited payload capacity and complex manufacturing are headwinds for the field. Anjarium is squarely focused on those challenges.
15
Funding: $54.6M
GeNeuro develops innovative treatments against inflammatory and degenerative disorders associated with endogenous retroviruses.
GeNeuro develops innovative treatments against inflammatory and degenerative disorders associated with endogenous retroviruses.
16
Funding: $45.3M
Ava is a patented multi-sensor bracelet, which allows women to precisely and conveniently predict fertile days. Ava uses AI for big data analytics to track personal fertility cycles.
Ava is a patented multi-sensor bracelet, which allows women to precisely and conveniently predict fertile days. Ava uses AI for big data analytics to track personal fertility cycles.
17
Funding: $33.4M
Sensimed AG, a Swiss company, has developed a unique non-invasive soft contact lens-based solution, the SENSIMED Triggerfish, with the aim of revolutionizing glaucoma management by providing an automated recording of continuous ocular dimensional change over 24 hours.
Sensimed AG, a Swiss company, has developed a unique non-invasive soft contact lens-based solution, the SENSIMED Triggerfish, with the aim of revolutionizing glaucoma management by providing an automated recording of continuous ocular dimensional change over 24 hours.
18
Funding: $21.3M
ProteoMediX is specialized in the identification of novel biomarkers for the early detection of cancer. The first product currently developed is a blood-based test that enables the diagnosis of prostate cancer with significantly higher accuracy than today's clinical standard.
ProteoMediX is specialized in the identification of novel biomarkers for the early detection of cancer. The first product currently developed is a blood-based test that enables the diagnosis of prostate cancer with significantly higher accuracy than today's clinical standard.
20
Funding: $16.2M
OnlineDoctor is an innovative Swiss-based platform that allows the user to diagnosed any skin problems quickly.
OnlineDoctor is an innovative Swiss-based platform that allows the user to diagnosed any skin problems quickly.
21
Funding: $701K
RegenHU is an innovative biomedical company that acts as a biosystem architect exploiting new biomanufacturing solutions in order to respond to the emerging challenges facing the biomedical industry.
RegenHU is an innovative biomedical company that acts as a biosystem architect exploiting new biomanufacturing solutions in order to respond to the emerging challenges facing the biomedical industry.
22
Funding: $8.1M
1Drop Diagnostics is a cutting edge medical diagnostics and life science company. They combine the best techniques from microfluidics, biochemistry, photonics and information technology to build high performance point-of-care diagnostics devices.
1Drop Diagnostics is a cutting edge medical diagnostics and life science company. They combine the best techniques from microfluidics, biochemistry, photonics and information technology to build high performance point-of-care diagnostics devices.
23
Funding: 3
ReHaptix is a clinically validated mHealth application assisting patients and healthcare professionals in monitoring the rehabilitation progress of patients suffering from upper limb impairments caused by a neurological injury, such as stroke, multiple sclerosis or Parkinson's disease.
ReHaptix is a clinically validated mHealth application assisting patients and healthcare professionals in monitoring the rehabilitation progress of patients suffering from upper limb impairments caused by a neurological injury, such as stroke, multiple sclerosis or Parkinson's disease.
24
Funding: €71.4K
Pattern’s Digital Culture technology will deliver pathogen identification (ID) and antibiotic susceptibility test (AST) results together within four hours.
Pattern’s Digital Culture technology will deliver pathogen identification (ID) and antibiotic susceptibility test (AST) results together within four hours.
25
Funding: CHF30K
Ophthorobotics is a swiss company committed to the development of medical robotics.
Ophthorobotics is a swiss company committed to the development of medical robotics.
26
Funding: CHF10K
SNAQ automates the processing of food images. Send us an image, we will recognize all food items and calculate the portion size for each item. Link this information with a nutrition database in order to get the carbohydrate, calorie and protein content of a meal.
SNAQ automates the processing of food images. Send us an image, we will recognize all food items and calculate the portion size for each item. Link this information with a nutrition database in order to get the carbohydrate, calorie and protein content of a meal.
28
sublimd is an award-winning medical software platform to radically reduce paperwork, enhance treatment outcome and revolutionize clinical research.
29
We deliver the next generation intelligence solution for insulin pumps, smart pens and other medical devices to make diabetes care smarter, more reliable, more accurate, and more reassuring than ever before.
★
See also:
